Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells + hyaluronic acid
- Development stage
- Unknown
- Lead developer
- Universiti Kebangsaan Malaysia
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) are an experimental cell therapy developed by the National University of Malaysia for the treatment of mild to moderate osteoarthritis. This therapeutic approach involves harvesting a patient's own bone marrow, isolating and expanding the mesenchymal stem cells ex vivo, and subsequently re-injecting them into the affected joint. In clinical trials, these cells are often administered in a carrier of hyaluronic acid (specifically Orthovisc) to improve cell retention and provide joint lubrication. The mechanism of action is believed to involve the secretion of bioactive factors that modulate the intra-articular inflammatory environment, reduce chondrocyte apoptosis, and potentially stimulate the regeneration of damaged articular cartilage.
- Brand names
- Orthovisc
- Other names
- autologous BM-MSCsbone marrow-derived mesenchymal stem cellsautologous mesenchymal stem cellsautologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells + hyaluronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells + hyaluronic acid.